ISRG: Stock Decline Doesn't Erase International Headwinds

What happened

Intuitive Surgical's 28% stock decline prompted a Seeking Alpha upgrade to Buy, citing long-term surgical robotics market growth. However, the DeepValue report maintains a WAIT rating, as the premium valuation at 47.8x P/E still prices in sustained mid-teens procedure growth and a successful DV5 upgrade cycle. While Q1'26 results showed solid execution—23% revenue growth and 16% procedure growth—the deceleration in OUS procedures to 19% (from 24%) and management's admission of China tender disruptions signal real near-term headwinds. The report flags that rising leasing mix and competitive entries from Medtronic and J&J could pressure pricing and placement momentum. Until OUS re-acceleration is confirmed and China stabilizes, the risk/reward remains unattractive despite the recent pullback.

Implication

If international momentum recovers and DV5 upgrades sustain ASP and utilization, the stock could approach $480 in the bull case. However, the base case implies limited upside from $401.50, so patience is warranted until the next 1-2 quarters confirm the growth trajectory.

Thesis delta

The upgrade article frames the 28% decline as a buying opportunity, but the DeepValue report's WAIT rating underscores that current valuation still ignores unresolved international placement risks. The delta is that while the long-term robotic surgery thesis remains intact, near-term headwinds from China, Europe budget pressure, and new competition have not yet been priced in, making the stock more of a show-me story than a clear buy.